Results 231 to 240 of about 114,065 (338)

Defective cell-autonomous signalling and antigenic polyreactivity of B-cell receptors from chronic lymphocytic leukaemia stereotyped subset 1. [PDF]

Nat Commun
Cocomazzi PG, Iatrou A, Minici C, Gounari M, Linder AT, Akpınaroğlu C, Patrone M, Broggini L, Frenquelli M, Sarrigeorgiou I, Lymberi P, Petrakis G, Koletsa T, Scarfò L, Agathangelidis A, Jumaa H, Maity PC, Ghia P, Stamatopoulos K, Degano M.   +19 more
europepmc   +1 more source

The Role of SAMHD1 in Viral Resistance and Transduction Efficiency Challenges in Pediatric Hematological Malignancies: Mechanistic Insights and Clinical Perspectives

European Journal of Haematology, EarlyView.
SAMHD1 regulates intracellular dNTP pools, influencing lentiviral transduction, gene therapy efficiency, and disease progression in pediatric hematological malignancies. Integrated bioinformatics and targeted strategies, including CRISPR and pharmacological inhibition, highlight its therapeutic potential.
Waseem Alzamzami
wiley   +1 more source

CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia. [PDF]

J Cell Mol Med
Beyar-Katz O, Benjamini O, Delgado J, Ruella M, Ram R, Grisariu S, Visentin A, Vandenberghe E, Gentile M, Avigdor A, Shimoni A, Shouval R, Marcus R, Schuster SJ, Ortiz-Maldonado V, Ghilardi G, Paruzzo L, Zuckerman T, Tadmor T, Fineman R, Amit O, Martinez-Cibrian N, Gabrielli G, Avni B, Minga E, Shem-Tov N, Scarfo L, Yerushalmi R, Nagler A, Leiba R, Danylesko I, Stamatopoulos K, Chatzikonstantinou T, Ghia P, Herishanu Y.   +34 more
europepmc   +1 more source

Relationship between co‐morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study

British Journal of Haematology, 2017
P. Strati, S. Parikh, K. G. Chaffee, N. Kay, T. Call, S. Achenbach, J. Cerhan, S. Slager, T. Shanafelt   +8 more
semanticscholar   +1 more source

Recombinant zoster vaccine induces superior immunogenicity compared with live varicella vaccine in allogeneic haematopoietic stem cell transplantation recipients

British Journal of Haematology, EarlyView.
Takaaki Ono, Takashi Okada, Ryo Ikeda, Mitsuru Yamashita, Katsumi Koyauchi, Fumisato Takagi, Miwa Adachi, Tomonari Takemura, Kozue Mitsui, Yasuyuki Nagata   +9 more
wiley   +1 more source

Rate of MGUS Progression to Haematological Malignancies: A Systematic Review

European Journal of Haematology, EarlyView.
ABSTRACT Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic pre‐cancerous condition that precedes plasma cell dyscrasias, including multiple myeloma (MM). Current clinical guidelines report that MGUS's rate of malignant progression to haematological malignancy (HM) is ~1% per year; however, reported rates have varied widely ...
Stephen James Quinn, Chris Cardwell, Lesley Ann Anderson, Charlene McShane   +3 more
wiley   +1 more source

The unfolded protein response influences therapy outcome and disease progression in chronic lymphocytic leukaemia. [PDF]

Sci Rep
Khan UT, Clarke K, Eagle G, Oates M, Hillmen P, Jayne S, Dyer MJS, Phipps A, Falciani F, Jenkins RE, Pettitt AR.   +10 more
europepmc   +1 more source

Real‐World Selection of Venetoclax‐Obinutuzumab Versus BTK Inhibitor Therapy for Treatment‐Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

European Journal of Haematology, EarlyView.
ABSTRACT Introduction Novel targeted agents have transformed the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including continuous BTK inhibitor (BTKi) therapy and time‐limited regimens such as venetoclax‐obinutuzumab (Ven‐O) and ibrutinib‐venetoclax (I + V).
Rebecca Tidswell, Carolyn Owen, Mona Shafey, Sarah Perry, Nanette Cox‐Kennett, Russell Sterrett, Anthea Peters, Robert Puckrin   +7 more
wiley   +1 more source

Addressing cardiovascular toxicities of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukaemia: practical recommendations for haematologists in central and eastern Europe. [PDF]

Cardiooncology
Aurer I, Bulj N, Demirevska L, Dragnić S, Dreisinger M, Goranova-Marinova V, Jakšić O, Lipar L, Rener K, Spassov B, Urošević I, Vukovic V, Žarić E, Zdravković M.   +13 more
europepmc   +1 more source

Cost‐Effectiveness of Venetoclax‐Based Treatment in Treatment‐Naïve Fit Patients With CLL Without TP53 Aberrations

European Journal of Haematology, EarlyView.
ABSTRACT The GAIA‐CLL13 trial showed that venetoclax‐obinutuzumab (Ven‐O) based regimens, with or without ibrutinib, offer superior efficacy compared to chemoimmunotherapy (CIT) with regards to progression free survival (PFS) in fit, treatment‐naïve (TN) CLL patients. However, their higher costs warrant a cost‐effectiveness evaluation.
Lars Holger Ehlers, Mark‐David Levin, Marjolein van der Klift, Morten Berg Jensen, Hoa Thi Tuyet Tran, Arnon P. Kater, Carsten Utoft Niemann   +6 more
wiley   +1 more source